Exploring CIRM-Like Qualities in Breast Cancer Therapy

This chapter explores the differences between therapeutic compounds for HR-positive, HER2-negative metastatic breast cancer, highlighting CIRM-like qualities in some agents like LSS. It discusses the implications of modulators versus degraders and the uncertainty surrounding their clinical efficacy and side effects.